Insider and congress filings
Quest Diagnostics Incorporated (DGX)
About Quest Diagnostics Incorporated
from the company's filings and listing- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Chief executive
- James E. Davis
- Employees
- 51,500
- Listed since
- Dec 17, 1996
- Market value
- $26.0B
- Price to earnings
- 24.7
- Earnings per share
- $9.65
- Dividend yield
- 1.41%
Earnings
6 reported quarters · next on Oct 20, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 23, 2026 | $3.12 | $2.82 | $3.0B | $3.0B | EPS beatRevenue beat |
| Q1 FY2026reported Apr 21, 2026 | $2.50 | $2.37 | $2.9B | $2.8B | EPS beatRevenue beat |
| Feb 10, 2026 | $2.42 | $2.36 | $2.8B | $2.8B | EPS beatRevenue beat |
| Q3 FY2025reported Oct 21, 2025 | $2.60 | $2.50 | $2.8B | $2.7B | EPS beatRevenue beat |
| Q2 FY2025reported Jul 22, 2025 | $2.62 | $2.57 | $2.8B | $2.7B | EPS beatRevenue in line |
| Q1 FY2025reported Apr 22, 2025 | $2.21 | $2.15 | $2.7B | $2.6B | EPS beatRevenue in line |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 6, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| James E. DavisChairman, Chief Executive Officer and President | $1.3M | $8.8M | $5.5M | $15.5M |
| Sam A. SamadExecutive Vice President and Chief Financial Officer | $693K | $2.2M | $1.5M | $4.4M |
| Catherine T. DohertyExecutive Vice President, Regional Businesses | $643K | $1.7M | $1.2M | $3.6M |
| Karthik KuppusamySenior Vice President, Clinical Solutions | $568K | $1.1M | $916K | $2.6M |
| Michael E. PrevoznikSenior Vice President and General Counsel | $550K | $1.1M | $882K | $2.6M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Blackrock, Inc. | $2.0B | 9,275,411 | +1.1% | 8.43% |
| Vanguard Capital Management LLC | $1.5B | 7,233,394 | +1.2% | 6.58% |
| Vanguard Portfolio Management LLC | $1.3B | 6,131,045 | +0.8% | 5.57% |
| State Street Corp | $1.2B | 5,516,643 | +2.5% | 5.02% |
| Price T Rowe Associates Inc | $1.2B | 5,444,986 | -13.5% | 4.95% |
| Boston Partners | $1.0B | 4,744,473 | +18.3% | 4.31% |
| Jpmorgan Chase & Co | $748.6M | 3,520,438 | -8.5% | 3.20% |
| Geode Capital Management, LLC | $662.6M | 3,137,873 | +1.7% | 2.85% |
| Morgan Stanley | $521.5M | 2,460,497 | -0.8% | 2.24% |
| Edgepoint Investment Group Inc. | $476.4M | 2,247,568 | +0.2% | 2.04% |
| Dimensional Fund Advisors LP | $421.4M | 1,988,048 | +2.0% | 1.81% |
| Bank Of America Corp | $410.2M | 1,935,133 | +10.4% | 1.76% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
14 filings of 378 on record| Insider | Action | Shares | Price | Value | Trade date | Delay |
|---|---|---|---|---|---|---|
| J. E. DavisCEO and President | Sold | 10,000 | $242.72 | $2.4M | Sep 1, 2026 | 2d |
| Michael E. PrevoznikSVP & General Counsel | Sold · 3 lines | 22,677 | $243.11 | $5.5M | Aug 28, 2026 | 3d |
| Mark E. DelaneySVP & Chief Commercial Officer | Sold | 1,600 | $235.18 | $376K | Jul 28, 2026 | 1d |
| Karthik KuppusamySVP, Clinical Solutions | Sold | 8,147 | $200.00 | $1.6M | Jun 4, 2026 | 4d |
| J. E. DavisCEO and President | Sold | 10,000 | $194.14 | $1.9M | Jun 1, 2026 | 1d |
| Michael E. PrevoznikSVP & General Counsel | Sold | 3,878 | $206.21 | $800K | Mar 5, 2026 | 1d |
| Patrick PlewmanSVP for Diagnostic Services | Sold | 2,855 | $206.21 | $589K | Mar 5, 2026 | 1d |
| Karthik KuppusamySVP, Clinical Solutions | Sold | 2,628 | $204.86 | $538K | Mar 4, 2026 | 2d |
| Catherine T. DohertyEVP, Regional Businesses | Sold | 5,558 | $206.21 | $1.1M | Mar 5, 2026 | 1d |
| Catherine T. DohertyEVP, Regional Businesses | Sold | 632 | $207.73 | $131K | Mar 3, 2026 | 1d |
| Michael E. PrevoznikSVP & General Counsel | Sold | 526 | $207.73 | $109K | Mar 3, 2026 | 1d |
| J. E. DavisCEO and President | Sold | 10,000 | $212.52 | $2.1M | Mar 2, 2026 | 2d |
| Patrick PlewmanSVP for Diagnostic Services | Sold | 410 | $207.73 | $85K | Mar 3, 2026 | 1d |
| Patrick PlewmanSVP for Diagnostic Services | Sold | 958 | $204.83 | $196K | Feb 19, 2026 | 1d |
One row is one filing. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count.
Congress trades in DGX
20 disclosures of 74 on record · median 31d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Julie JohnsonJointFiled late | Stock | Sale | $1,001 - $15,000 | +34.0%S&P +12.1% · vs S&P 500 +21.9% | Oct 30, 2025 | Aug 5, 2026 | 279d |
| Julie JohnsonJointFiled late | Stock | Purchase | $1,001 - $15,000 | +34.0%S&P +12.1% · vs S&P 500 +21.9% | Oct 30, 2025 | Aug 5, 2026 | 279d |
| Alan ArmstrongSelfFiled late | Stock | Purchase | $1,001 - $15,000 | +20.4%S&P +20.2% · vs S&P 500 +0.2% | Mar 27, 2026 | Jul 21, 2026 | 116d |
| Alan ArmstrongSelfFiled late | Stock | Purchase | $1,001 - $15,000 | +19.4%S&P +20.7% · vs S&P 500 -1.2% | Mar 30, 2026 | Jul 21, 2026 | 113d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +14.6%S&P +11.6% · vs S&P 500 +3.0% | Feb 17, 2026 | Mar 9, 2026 | 20d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +29.1%S&P +9.8% · vs S&P 500 +19.3% | Jan 29, 2026 | Feb 6, 2026 | 8d |
| Julia LetlowFiled late | Stock | Sale | $1,001 - $15,000 | +35.6%S&P +20.4% · vs S&P 500 +15.2% | Jul 24, 2025 | Jan 13, 2026 | 173d |
| Julia LetlowFiled late | Stock | Purchase | $1,001 - $15,000 | +31.9%S&P +38.6% · vs S&P 500 -6.7% | Apr 28, 2025 | Jan 13, 2026 | 260d |
| Julie JohnsonJoint | Stock | Sale | $1,001 - $15,000 | +31.7%S&P +11.6% · vs S&P 500 +20.1% | Nov 3, 2025 | Dec 11, 2025 | 38d |
| Carol D. Miller | Stock | Sale | $1,001 - $15,000 | +36.0%S&P +36.0% · vs S&P 500 +0.1% | Mar 10, 2025 | Apr 11, 2025 | 32d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +55.7%S&P +27.6% · vs S&P 500 +28.2% | Jan 17, 2025 | Feb 6, 2025 | 20d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +45.6%S&P +27.7% · vs S&P 500 +17.9% | Nov 12, 2024 | Dec 5, 2024 | 23d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +46.8%S&P +30.2% · vs S&P 500 +16.6% | Nov 15, 2024 | Dec 5, 2024 | 20d |
| Ro Khanna | Stock | Exchange | n/a | n/a | Mar 5, 2024 | Mar 6, 2024 | 1d |
| Ro Khanna | Stock | Sale | n/a | n/a | Mar 5, 2024 | Mar 6, 2024 | 1d |
| Tommy TubervilleJoint | Stock | Sale (Partial) | $15,001 - $50,000 | +68.6%S&P +62.7% · vs S&P 500 +5.9% | Jan 3, 2024 | Feb 14, 2024 | 42d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +74.6%S&P +67.0% · vs S&P 500 +7.5% | Dec 5, 2023 | Jan 4, 2024 | 30d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +71.3%S&P +67.0% · vs S&P 500 +4.3% | Dec 4, 2023 | Jan 4, 2024 | 31d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +81.0%S&P +82.4% · vs S&P 500 -1.4% | Oct 31, 2023 | Nov 8, 2023 | 8d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +85.2%S&P +70.9% · vs S&P 500 +14.3% | Sep 6, 2023 | Oct 6, 2023 | 30d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Members of Congress reporting a position
1 member · estimate, as of Sep 10, 20261 member reports a position (estimated). The largest estimated position is in the $1,001 - $15,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Gilbert Ray Cisneros, Jr. | Democrat · House | $1,001 - $15,000 | <0.1% |
Estimate, as of Sep 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Awards, option exercises and gifts (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Michael E. PrevoznikSVP & General Counsel | Option exercise | 22,677 | Aug 28, 2026 |
| Michael E. PrevoznikSVP & General Counsel | Gift | 1,000 | Aug 28, 2026 |
| Patrick PlewmanSVP for Diagnostic Services | Form 4 | 46 | Jul 22, 2026 |
| Vicky B. GreggDirector | Stock award | 72 | Jul 22, 2026 |
| Robert B. CarterDirector | Form 4 | 11 | Jul 22, 2026 |
| Mark E. DelaneySVP & Chief Commercial Officer | Form 4 | 34 | Jul 22, 2026 |
| Wright Lassiter IIIDirector | Form 4 | 6 | Jul 22, 2026 |
| Sam SamadExecutive Vice President & CFO | Stock award | 102 | Jul 22, 2026 |
| Timothy L. MainDirector | Form 4 | 21 | Jul 22, 2026 |
| Karthik KuppusamySVP, Clinical Solutions | Form 4 | 37 | Jul 22, 2026 |
| Timothy C. WentworthDirector | Stock award | 144 | Jul 1, 2026 |
| Karthik KuppusamySVP, Clinical Solutions | Option exercise | 8,147 | Jun 4, 2026 |
| Timothy M. RingDirector | Stock award | 1,142 | May 20, 2026 |
| Robert B. CarterDirector | Stock award | 1,142 | May 20, 2026 |
| Vicky B. GreggDirector | Stock award | 1,142 | May 20, 2026 |
| Luis DiazDirector | Stock award | 1,142 | May 20, 2026 |
| Timothy L. MainDirector | Stock award | 1,142 | May 20, 2026 |
| Timothy C. WentworthDirector | Stock award | 1,142 | May 20, 2026 |
| Tracey DoiDirector | Stock award | 1,142 | May 20, 2026 |
| Wright Lassiter IIIDirector | Stock award | 1,142 | May 20, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling DGX?
Across the 14 most recent open-market filings shown here, 0 were purchases and 14 were sales.
Which members of Congress have traded DGX?
Julie Johnson, Alan Armstrong, Ro Khanna, Julia Letlow, Carol D. Miller, Tommy Tuberville disclosed DGX transactions in the filings shown here.
Which members of Congress hold DGX?
1 member of Congress reports a position in DGX in the estimate we hold as of Sep 10, 2026. The largest estimated position belongs to Gilbert Ray Cisneros, Jr.. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is DGX in the S&P 500 or the Nasdaq 100?
Quest Diagnostics Incorporated is a current member of the S&P 500, per the membership list we hold as of Sep 10, 2026. Current members of either index get a page here whatever their filing history.
How quickly are DGX trades disclosed?
Insider filings on this page reached the public a median of 1 days after the transaction, against the two business days Form 4 allows. Congressional disclosures took a median of 31 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.